Molecule Information
General Information of the Molecule (ID: Mol00958)
Name |
Erythromycin esterase (EREA2)
,Vibrio cholerae
|
||||
---|---|---|---|---|---|
Synonyms |
ereA2; Erythromycin esterase
Click to Show/Hide
|
||||
Molecule Type |
Protein
|
||||
Gene Name |
ereA2
|
||||
Sequence |
MTWRTTRTLLQPQKLEFNEFEILNPVVEGARIVGIGEGAHFVAEFSLARASLIRYFVERH
DFNAIGLECGAIQASRLSEWLNSTAGAHELERFSDTLTFSLYGSVLIWVKSYLRESGRKL QLVGIDLPNTLNPRDDLAQLAEIIQVIDHLMKPHVDALTQLLTSIDGQSAVISSAKWGEL ETAQQEKAISGVTRLKLRLASLAPVLKNHVNSDFFRKASDRIESIEYTLETLRVMKAFFD GTSLEGDTSVRDSYMAGVVDGMVRANPDVRIILLAHNNHLQKTPVSFSGELTAVPMGQHL AEREEGDYRAIAFTHLGLTVPEMHFPSPDSPLGFSVVTTPADAIREDSVEQYVIDACGKE DSCLTLTDDPMEAKRMRSQSASVETNLSEAFDAIVCVPSAGKDSLVAL Click to Show/Hide
|
||||
Uniprot ID | |||||
Click to Show/Hide the Complete Species Lineage | |||||
Type(s) of Resistant Mechanism of This Molecule
DISM: Drug Inactivation by Structure Modification
Drug Resistance Data Categorized by Drug
Approved Drug(s)
6 drug(s) in total
Ampicillin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Disease Class: Vibrio cholerae infection | [1] | |||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Resistant Drug | Ampicillin | |||
Molecule Alteration | Expression | Inherence |
||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae PG153/1 | 666 | ||
Vibrio cholerae PG170 | 666 | |||
Vibrio cholerae PL96 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA5, ereA2 lead to drug resistance. |
Chloramphenicol
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Disease Class: Vibrio cholerae infection | [1] | |||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Resistant Drug | Chloramphenicol | |||
Molecule Alteration | Expression | Inherence |
||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae PG153/1 | 666 | ||
Vibrio cholerae PG170 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA5, ereA2 lead to drug resistance. |
Ciprofloxacin XR
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Disease Class: Vibrio cholerae infection | [1] | |||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Resistant Drug | Ciprofloxacin XR | |||
Molecule Alteration | Expression | Inherence |
||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae PG153/1 | 666 | ||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA5, ereA2 lead to drug resistance. |
Furazolidone
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Disease Class: Vibrio cholerae infection | [1] | |||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Resistant Drug | Furazolidone | |||
Molecule Alteration | Expression | Inherence |
||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae PG153/1 | 666 | ||
Vibrio cholerae PG170 | 666 | |||
Vibrio cholerae PL96 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA5, ereA2 lead to drug resistance. |
Nalidixic acid
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Disease Class: Vibrio cholerae infection | [1] | |||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Resistant Drug | Nalidixic acid | |||
Molecule Alteration | Expression | Inherence |
||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae PG153/1 | 666 | ||
Vibrio cholerae PG170 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA5, ereA2 lead to drug resistance. |
Trimethoprim
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Disease Class: Vibrio cholerae infection | [1] | |||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Resistant Drug | Trimethoprim | |||
Molecule Alteration | Expression | Inherence |
||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae PG153/1 | 666 | ||
Vibrio cholerae PG170 | 666 | |||
Vibrio cholerae PL96 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA5, ereA2 lead to drug resistance. |
Investigative Drug(s)
1 drug(s) in total
Sulfamethizole/Sulfadiazine
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Disease Class: Vibrio cholerae infection | [1] | |||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Resistant Drug | Sulfamethizole/Sulfadiazine | |||
Molecule Alteration | Expression | Inherence |
||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae PG153/1 | 666 | ||
Vibrio cholerae PG170 | 666 | |||
Vibrio cholerae PL96 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA5, ereA2 lead to drug resistance. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.